Research Keyword: tau phosphorylation

Sporoderm-removed ganoderma lucidum spore powder (S-GLSP) alleviates neuroinflammation injury by regulating microglial polarization through inhibition of NLRP3 inflammasome activation

mycolabadmin

Researchers found that sporoderm-removed Ganoderma lucidum spore powder (S-GLSP) protects against Alzheimer’s disease by reducing brain inflammation. The supplement works by shifting immune cells in the brain called microglia from a harmful pro-inflammatory state to a protective anti-inflammatory state. This is accomplished by blocking the NLRP3 inflammasome, a key trigger of brain inflammation. In animal and cell studies, S-GLSP improved memory, reduced neuronal damage, and decreased harmful tau protein accumulation.

Read More »

Microbial links to Alzheimer’s disease

mycolabadmin

Researchers are investigating whether common infections from bacteria, viruses, and fungi might trigger or worsen Alzheimer’s disease. Studies show that pathogens like the bacteria that causes gum disease and certain herpes viruses can reach the brain and trigger inflammation and amyloid-beta accumulation, key features of Alzheimer’s. While the evidence is promising, scientists haven’t yet proven whether these infections cause Alzheimer’s or simply make existing disease worse.

Read More »

Identification of potential neuroprotective compound from Ganoderma lucidum extract targeting microtubule affinity regulation kinase 4 involved in Alzheimer’s disease through molecular dynamics simulation and MMGBSA

mycolabadmin

Researchers used computer simulations to test five compounds from Reishi mushrooms against Alzheimer’s disease. They found that two compounds, ganoderic acid A and ganoderenic acid B, showed strong potential for blocking a harmful protein involved in the disease. These findings suggest Reishi mushrooms could be a source for new Alzheimer’s treatments, though further laboratory testing is needed.

Read More »
Scroll to Top